Somewhat Positive Media Coverage Somewhat Unlikely to Impact AxoGen (AXGN) Share Price
News headlines about AxoGen (NASDAQ:AXGN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.7884599516911 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several research firms have commented on AXGN. Leerink Swann boosted their target price on AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. Lake Street Capital boosted their target price on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Wedbush reissued a “buy” rating and issued a $27.00 target price (up from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of AxoGen in a report on Friday, January 5th. Finally, BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.33.
AxoGen (NASDAQ AXGN) opened at $27.55 on Wednesday. AxoGen has a one year low of $9.55 and a one year high of $31.70. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93. The firm has a market capitalization of $944.40, a price-to-earnings ratio of -68.88 and a beta of 0.40.
In other news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamie Mark Grooms sold 38,405 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total value of $1,011,971.75. The disclosure for this sale can be found here. Insiders sold 1,293,990 shares of company stock valued at $26,494,898 in the last 90 days. Company insiders own 9.33% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/01/31/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-axogen-axgn-share-price.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.